Whilst these peptides represent promising therapeutic targets in diseases where mitochondrial dysfunction is a key driver [64,66], the essential role of mitochondrial JNK in therapy-induced apoptotic response likely limits their use as cancer treatments. Here, MAPK8 is linked to cancer.